Literature DB >> 17414582

Role of endothelins in hypertension.

Carlos Feldstein1, Carlos Romero.   

Abstract

There are three peptides of endothelial origin, called endothelins (ETs), having different receptors that mediate a potent vasoconstrictor effect and also a mild vasodilation. Their renal effects are characterized by natriuresis in spite of the renal vasoconstriction. This effect, along with the stimulation of ETs by high sodium intake, suggests that ETs may be responsible for maintaining sodium balance when the renin angiotensin system is depressed. ET is activated in deoxycorticosterone acetate (DOCA) salt hypertension models and salt-sensitive hypertension. In humans, the role of ET seems to be similar to that shown in experimental animals; in both, ET participates in the regulation of salt metabolism. Salt-sensitive patients exhibit a blunted renal ET-1 response during sodium load. The role of ETs in humans has been investigated with use of nonspecific ET receptor blockers that inhibit the vasoconstriction and vasodilator components of ET. However, the effects of ET blockade should be investigated with ETA receptor blockers that mediate vasoconstriction alone. Effects of ET blockade should also be evaluated with respect to stimulation of oxidative stress and tissue damage, important mechanisms responsible for tissue fibrosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414582     DOI: 10.1097/01.pap.0000249912.02763.65

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  16 in total

Review 1.  Key advances in antihypertensive treatment.

Authors:  Ludovit Paulis; Ulrike M Steckelings; Thomas Unger
Journal:  Nat Rev Cardiol       Date:  2012-03-20       Impact factor: 32.419

Review 2.  Endothelin B receptor, a new target in cancer immune therapy.

Authors:  Lana E Kandalaft; Andrea Facciabene; Ron J Buckanovich; George Coukos
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 3.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

4.  Effects of silencing endothelin-1 on invasion and vascular formation in lung cancer.

Authors:  Zhen-Yu Zhang; Li-Li Chen; Wei Xu; Keshavraj Sigdel; Xing-Tang Jiang
Journal:  Oncol Lett       Date:  2017-04-11       Impact factor: 2.967

5.  Inhibitory effect of ETB receptor on Na(+)-K(+) ATPase activity by extracellular Ca(2+) entry and Ca(2+) release from the endoplasmic reticulum in renal proximal tubule cells.

Authors:  Yan Liu; Jian Yang; Hongmei Ren; Duofen He; Annabelle Pascua; M Ines Armando; Chengming Yang; Lin Zhou; Robin A Felder; Pedro A Jose; Chunyu Zeng
Journal:  Hypertens Res       Date:  2009-08-07       Impact factor: 3.872

6.  Phospholipase C-delta1 modulates sustained contraction of rat mesenteric small arteries in response to noradrenaline, but not endothelin-1.

Authors:  Christopher J Clarke; Simon Forman; James Pritchett; Vasken Ohanian; Jacqueline Ohanian
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

7.  Renal cell carcinoma and arterial hypertension.

Authors:  Milan Stojanovic; Branislav Goldner; Dusan Ivkovic
Journal:  Clin Exp Nephrol       Date:  2009-01-29       Impact factor: 2.801

Review 8.  Endothelin-1, aging and hypertension.

Authors:  Brian L Stauffer; Christian M Westby; Christopher A DeSouza
Journal:  Curr Opin Cardiol       Date:  2008-07       Impact factor: 2.161

9.  Divergent roles of nitric oxide and rho kinase in vasomotor regulation of human retinal arterioles.

Authors:  Travis W Hein; Robert H Rosa; Zhaoxu Yuan; Elizabeth Roberts; Lih Kuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-10-22       Impact factor: 4.799

Review 10.  New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Authors:  Omar Azzam; Marcio G Kiuchi; Jan K Ho; Vance B Matthews; Leslie Marisol Lugo Gavidia; Janis M Nolde; Revathy Carnagarin; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2019-09-10       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.